PMID- 18388923
OWN - NLM
STAT- MEDLINE
DCOM- 20080819
LR  - 20171116
IS  - 1525-0024 (Electronic)
IS  - 1525-0016 (Linking)
VI  - 16
IP  - 5
DP  - 2008 May
TI  - Administering plasmid DNA encoding tumor vessel-anchored IFN-alpha for localizing 
      gene product within or into tumors.
PG  - 901-6
LID - 10.1038/mt.2008.40 [doi]
AB  - Tumor-targeted gene delivery has been intensively studied in the field of gene 
      therapy, but no attention has been given to targeting the therapeutic gene 
      products, which are transcribed and translated from the injected genes, into 
      tumors. Targeting immune stimulatory gene products into tumors is the key to 
      triggering tumor-specific CD8(+) T-cell responses and reducing systemic toxicity. 
      To target the gene products generated from the injected genes into tumors, genes 
      encoding the tumor-targeted fusion gene product were generated and administered 
      locally and systemically via electroporation. As anticipated, administration of a 
      therapeutic gene encoding IFN-alpha and the tumor vessel-targeted peptide CDGRC 
      fusion gene product minimizes the leakage of immunostimulatory cytokine from 
      tumors into the blood circulation, increases the infiltration of CD8(+) T cells 
      into tumors, induces a high magnitude of cytotoxic T-cell lysis (CTL) activity, 
      and reduces tumor vessel density. As a result, tumor growth was more 
      significantly inhibited by administering the IFN-alpha-CDGRC gene than by 
      administering the wild-type IFN-alpha gene. The same result was obtained with the 
      systemic administration of the tumor-targeted IFN-alpha gene. This gene 
      product-based tumor-targeted gene therapy approach could complement any other 
      tumor-targeted gene delivery method for improving tumor-targeting efficiency.
FAU - Craig, Ryan
AU  - Craig R
AD  - Department of Comparative Biomedical Sciences, Louisiana State University, Baton 
      Rouge, Louisiana 70803, USA.
FAU - Cutrera, Jeffry
AU  - Cutrera J
FAU - Zhu, Shiguo
AU  - Zhu S
FAU - Xia, Xueqing
AU  - Xia X
FAU - Lee, Yong-Hwan
AU  - Lee YH
FAU - Li, Shulin
AU  - Li S
LA  - eng
GR  - R01CA120895/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20080318
PL  - United States
TA  - Mol Ther
JT  - Molecular therapy : the journal of the American Society of Gene Therapy
JID - 100890581
RN  - 0 (Interferon-alpha)
RN  - 9007-49-2 (DNA)
RN  - EC 3.4.11.2 (CD13 Antigens)
SB  - IM
MH  - Amino Acid Sequence
MH  - Animals
MH  - Base Sequence
MH  - CD13 Antigens/biosynthesis
MH  - CD8-Positive T-Lymphocytes/metabolism
MH  - DNA/*chemistry
MH  - Female
MH  - *Gene Transfer Techniques
MH  - Genetic Therapy/*methods
MH  - Interferon-alpha/*metabolism
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C3H
MH  - Molecular Sequence Data
MH  - Plasmids/*metabolism
EDAT- 2008/04/05 09:00
MHDA- 2008/08/20 09:00
CRDT- 2008/04/05 09:00
PHST- 2008/04/05 09:00 [pubmed]
PHST- 2008/08/20 09:00 [medline]
PHST- 2008/04/05 09:00 [entrez]
AID - S1525-0016(16)31704-X [pii]
AID - 10.1038/mt.2008.40 [doi]
PST - ppublish
SO  - Mol Ther. 2008 May;16(5):901-6. doi: 10.1038/mt.2008.40. Epub 2008 Mar 18.